Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Retained Earnings (2023 - 2026)

MBX Biosciences has reported Retained Earnings over the past 4 years, most recently at -$248.0 million for Q1 2026.

  • Quarterly results put Retained Earnings at -$248.0 million for Q1 2026, down 468024.53% from a year ago — trailing twelve months through Mar 2026 was -$248.0 million (down 468024.53% YoY), and the annual figure for FY2025 was $286000.0, up 420.0%.
  • Retained Earnings reached -$248.0 million in Q1 2026 per MBX's latest filing, down from $286000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $286000.0 in Q4 2025 and bottomed at -$248.0 million in Q1 2026.
  • Median Retained Earnings over the past 4 years was -$98.8 million (2023), compared with a mean of -$103.5 million.
  • The largest annual shift saw Retained Earnings soared 420.0% in 2025 before it tumbled 468024.53% in 2026.
  • Over 4 years, Retained Earnings stood at -$75.6 million in 2023, then skyrocketed by 100.07% to $55000.0 in 2024, then skyrocketed by 420.0% to $286000.0 in 2025, then plummeted by 86813.29% to -$248.0 million in 2026.
  • Business Quant data shows Retained Earnings for MBX at -$248.0 million in Q1 2026, $286000.0 in Q4 2025, and -$202.4 million in Q3 2025.